The Strong Dollar Squeeze
Across 2 sectors, 27 of 33 filers are signaling falling disclosed risk. Accelerated into 2025Q2, since cooling. Direction flipped — 2024Q1 was 67% falling; 2026Q2 now 83% rising. Reached 10 sectors at its 2025Q3 peak, now 2 sectors. Primarily a risk story (51%), with a cost overlay (38%). One disclosure notes "net sales were negatively affected by $2.4 billion in currency exchange rate fluctuations."
Multinational corporations across pharma and industrial gases are reporting that a stronger U.S. dollar is materially eroding international sales, operating income, and gross margins, with some offsetting through pricing and cost initiatives.
DISTINCT NEW FILERS PER QUARTER
✦ WHAT THE DIFF CAUGHT
Language shifts from backward-looking quantified headwinds (2–4% sales impact, $10–14M income swings) to present-tense risk management and mitigation tactics (pricing actions, derivative hedging), suggesting companies are moving from absorbing currency hits to actively defending margins.
REPRESENTATIVE SIGNAL FROM FILINGS
“net sales were negatively affected by $2.4 billion in currency exchange rate fluctuations”
Currency exchange rate fluctuations negatively impacted net sales by $2.4 billion.
“17-percentage-point impact of unfavorable foreign exchange translation, driven primarily by the weakening of the Mexican peso”
Weakening of the Mexican peso created a 17-percentage-point headwind to operating profit.
DRIVERS